ReviewInternational journal of molecular sciences2018
Diabetic Retinopathy: Pathophysiology and Treatments.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04742829 (Evaluation of the Effect of a Therapy With INTRAVIT® Tablets on Retinal Edema, Retinal Sensitivity and Visual Acuity in the Course of Diabetic Retinopathy), which is not on this map. Cited by 708 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Effect of a Therapy With INTRAVIT® Tablets on Retinal Edema, Retinal Sensitivity and Visual Acuity in the Course of Diabetic Retinopathy
Who cites it
708 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,305 citations in OpenAlex.
- Diagnostic accuracy and clinical performance of deep learning models for grading diabetic retinopathy: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies.Frontiers in pharmacology · 2026Pooled it
- Short-Term and Long-Term Effects of Bariatric Surgery on Diabetic Retinopathy: A Systematic Review.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Systematic review on biomarker potential of vitreous microRNA in retinal disease.Frontiers in ophthalmology · 2025Pooled it
- Effect of combined mature cataract surgery and intravitreal ranibizumab injection in eyes with pre-existing diabetic macular edema.BMC ophthalmology · 2025Trial
- In situ bioactive nanocoating enables transocular delivery of permeable drug for dual-location intervention of ocular surface and fundus disorders.Bioactive materials · 2027Article
- Multimodal Retinal Structural and Functional Tests Identify Local and Layer-Related Alterations in Early Type 2 Diabetes.Investigative ophthalmology & visual science · 2026Article
- Endocrine-Metabolic Crosstalk Between Diabetes Mellitus and Hypothyroidism: From Network Mechanisms to Translational Stratification.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- SLC7A11-mediated disulfidptosis underlies the pathogenesis of proliferative diabetic retinopathy.Eye and vision (London, England) · 2026Article
- Phosphodiesterase 5 inhibitor use and incident diabetic retinopathy in men with erectile dysfunction and type 2 diabetes: a propensity-matched cohort study.Eye (London, England) · 2026Article
- Role of systemic hypoxia in the progression of diabetic retinopathy: a propensity-matched retrospective cohort study.BMJ open ophthalmology · 2026Article
- Alpinia Oxyphylla-Shenqi Siwu Decoction protects against high glucose-induced retinal pigment epithelial cell injury involving the PI3K/AKT/mTOR pathway.International ophthalmology · 2026Article
- [Work reintegration in patients treated for diabetic macular edema].Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Long-Acting RXR Agonism Preserves Retinal Function and Modulates Inflammation in Diabetic Retinopathy.Diabetes · 2026Article
- Intermittent fasting in diabetic retinopathy: microbiome modulation, mechanisms, and clinical insights.Cardiovascular endocrinology & metabolism · 2026Review
- Effects of Curcumin on Inflammation in a Rat Model of Diabetic Retinopathy.Life (Basel, Switzerland) · 2026Article
- Placental Growth Factor in Diabetic Retinopathy: Disease-Selective Signaling and Mechanistic Rationale for Targeted Therapy.International journal of molecular sciences · 2026Review
- Annexin A1 as a Key Modulator of Inflammatory, Glial, and Angiogenic Signaling Pathways in Diabetic Retinopathy.Investigative ophthalmology & visual science · 2026Article
- Article
- Advancing Treatment of Degenerative Eye Diseases at the Nanoscale.Smart medicine · 2026Review
648 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is the most common complication of diabetes mellitus (DM). It has long been recognized as a microvascular disease. The diagnosis of DR relies on the detection of microvascular lesions. The treatment of DR remains challenging. The advent of anti-vascular endothelial growth factor (VEGF) therapy demonstrated remarkable clinical benefits in DR patients; however, the majority of patients failed to achieve clinically-significant visual improvement. Therefore, there is an urgent need for the development of new treatments. Laboratory and clinical evidence showed that in addition to microvascular changes, inflammation and retinal neurodegeneration may contribute to diabetic retinal damage in the early stages of DR. Further investigation of the underlying molecular mechanisms may provide targets for the development of new early interventions. Here, we present a review of the current understanding and new insights into pathophysiology in DR, as well as clinical treatments for DR patients. Recent laboratory findings and related clinical trials are also reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.